Drug Profile
Gemifloxacin
Alternative Names: ARB-FV0127; Factive; Gemifloxacin mesylate; LB 20304; LB 20304a; SB 265805Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer Abbott Canada; Chiesi USA; LG Chem; Menarini; Pfizer
- Class Antibacterials; Cyclopropanes; Fluoroquinolones; Imines; Naphthyridines; Pyrrolidines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Urinary tract infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
- 26 Jul 2016 The US FDA approved label for gemifloxacin carries a boxed warning
- 22 Oct 2014 Launched prior to this date for Bacterial infections in Brazil, Chile, Mexico, South Africa & Turkey (PO)